Zentalis Pharmaceuticals, Inc. (ZNTL) has reported a narrowed net loss for the second quarter of 2025 and is continuing to advance its lead clinical candidate.

**Financial Performance and Runway:**
On August 6, 2025, Zentalis Pharmaceuticals reported its Q2 2025 financial results, with a GAAP earnings per share (EPS) of $0.37, which significantly outperformed analyst expectations of a $(0.59) loss. The company reported no revenue, consistent with its pre-commercial development phase. Research and development expenses decreased to $27.6 million from $48.4 million in Q2 2024, a 43% reduction primarily due to decreases in clinical expenses, laboratory services, and drug manufacturing. General and administrative expenses also dropped by 49.7% compared to Q2 2024, largely due to reductions in jobs and consulting. As of June 30, 2025, Zentalis maintained a strong financial position with $303.4 million in cash, cash equivalents, and marketable securities, which the company expects to be sufficient to fund its operations into late 2027. This cash position is anticipated to last beyond the expected topline data from its ongoing DENALI clinical study.

**Clinical Pipeline Updates:**
Zentalis's lead candidate, azenosertib, a WEE1 inhibitor, is advancing in the Phase 2 DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Topline data from the DENALI Phase 2 trial is expected by year-end 2026, with the potential to support an accelerated approval, subject to FDA review. The company had previously reported updated clinical data from Part 1b of the DENALI trial in March 2025, showing a 34.9% objective response rate and a 6.3-month median duration of response in heavily pretreated patients. The first patient dosing in DENALI Part 2a clinical trial occurred in May 2025.

In June 2024, the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on three of Zentalis Pharmaceuticals' studies of azenosertib, including the DENALI trial. This decision followed the deaths of two patients in the DENALI study, presumably due to sepsis. The company stated it was working closely with the FDA to resolve the hold and was proceeding with the release of topline results from Cohort 1b of the DENALI trial.

**Corporate and Other Developments:**
Zentalis Pharmaceuticals announced inducement grants of stock options to newly hired employees on June 2, 2025, July 1, 2025, and September 2, 2025. These grants are part of the company's 2022 Employment Inducement Incentive Award Plan and are intended to attract new talent.

On August 26, 2025, James B. Bucher, JD, was appointed as Chief Legal Officer and Corporate Secretary. The company is also scheduled to participate in upcoming investor conferences, with an announcement made on August 28, 2025.

The next earnings publication date is estimated to be around November 11, 2025, based on previous reporting dates.